Answers are grounded in this paper and cite their sources.
HER2 is currently the only validated marker to select breast cancer patients for anti-HER2 treatment; however, it is becoming evident that HER2-positive breast cancer is a heterogeneous disease. In addition, more and more new anti-HER2 treatments are becoming available. There is a need to identify markers of sensitivity to different treatments to move in the direction of treatment personalization. This study identified PIK3CA mutations as a potential predictive marker of resistance to dual anti-HER2 treatment that should be further studied in breast cancer.
No takes yet. Share an insight, caveat, or question.
Guarneri et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: